Overview of bile acid signaling in the cardiovascular system

Zhang, Rou; Ma, Wen-Qi; Fu, Meng-Jun; Li, Juan; Hu, Chunhua; Chen, Yi; Zhou, Mimi; Gao, Zhijie; He, Yingli

doi:10.12998/wjcc.v9.i2.308

Cited by 21 publications

(17 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study suggests that chenodeoxycholic acid enhances lipoprotein clearance to safeguard against atherosclerosis and improves cardiac function and remodeling after a myocardial infarction (MI). 44 Our pathway analysis also suggested that the bile acid pathway was implicated in the carfilzomib-CVAE. Our pilot study has shed some light on the involvement of mitochondrial dysfunction in carfilzomib-CVAE.…”

Section: Discussionmentioning

confidence: 62%

“…Our study also identified the glycoconjugate of chenodeoxycholic acid to have different post‐baseline/baseline ratios between CVAE and no‐CVAE patients. A study suggests that chenodeoxycholic acid enhances lipoprotein clearance to safeguard against atherosclerosis and improves cardiac function and remodeling after a myocardial infarction (MI) 44 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Shabnaz,

Nguyen,

Williams

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify those at high risk prior to carfilzomib treatment and to explore the mechanisms of carfilzomib‐CVAE to inform potential strategies to protect patients from this cardiotoxicity. Global metabolomic profiling was performed on the baseline and post‐baseline plasma samples of 60 MM patients treated with carfilzomib‐based therapy, including 31 who experienced CVAE, in a prospective cohort study. Baseline metabolites and post‐baseline/baseline metabolite ratios that differ between the CVAE and no‐CVAE patients were identified using unadjusted and adjusted methods. A baseline metabolomic risk score was created to stratify patients. We observed a lower abundance of tauroursodeoxycholic acid (T‐UDCA) in CVAE patients at baseline (odds ratio [OR] = 0.47, 95% confidence interval [CI] = 0.21–0.94, p = 0.044) compared with the no‐CVAE patients. A metabolite risk score was able to stratify patients into three risk groups. The area under the receiver‐operating curve of the model with clinical predictors and metabolite risk score was 0.93. Glycochenodeoxycholic acid (OR = 0.56, 95% CI = 0.31–0.87, p = 0.023) was significantly lower in post‐baseline/baseline ratios of CVAE patients compared with no‐CVAE patients. Following metabolomic analysis, we created a baseline metabolite risk score that can stratify MM patients into different risk groups. The result also provided intriguing clues about the mechanism of carfilzomib‐CVAE and potential cardioprotective strategies.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Shabnaz,

Nguyen,

Williams

et al. 2024

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Some studies have found that primary BA levels are increased and secondary BA levels are decreased in patients with chronic heart failure. 119 Given that secondary BAs are generated from primary BAs by intestinal microbes, 120 this suggests that intestinal microbes are related to heart failure. As mentioned earlier, PAGln plays a role in the formation of blood clots, and it has also been found to play an important role in heart failure.…”

Section: Gut Microbiota In Age-related Cardiovascular Diseasesmentioning

confidence: 99%

Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms

Liu,

He,

Zhang

et al. 2023

Gut Microbes

View full text Add to dashboard Cite

The global population is aging and age-related cardiovascular disease is increasing. Even after controlling for cardiovascular risk factors, readmission and mortality rates remain high. In recent years, more and more in-depth studies have found that the composition of the gut microbiota and its metabolites, such as trimethylamine N-oxide (TMAO), bile acids (BAs), and short-chain fatty acids (SCFAs), affect the occurrence and development of age-related cardiovascular diseases through a variety of molecular pathways, providing a new target for therapy. In this review, we discuss the relationship between the gut microbiota and age-related cardiovascular diseases, and propose that the gut microbiota could be a new therapeutic target for preventing and treating cardiovascular diseases.

show abstract

“…BAs also prevent bacteria from overgrowth and decrease inflammation [ 154 ]. More importantly, BAs are also closely associated with CVDs [ 155 ]. For example, BAs levels in the feces of patients with CVDs are different from those in healthy individuals [ 156 ].…”

Section: The Role Of the Gut Microbiota In Health And Diseasesmentioning

confidence: 99%

The role of the gut microbiota in health and cardiovascular diseases

Wang

Zhang

et al. 2022

Mol Biomed

View full text Add to dashboard Cite

The gut microbiota is critical to human health, such as digesting nutrients, forming the intestinal epithelial barrier, regulating immune function, producing vitamins and hormones, and producing metabolites to interact with the host. Meanwhile, increasing evidence indicates that the gut microbiota has a strong correlation with the occurrence, progression and treatment of cardiovascular diseases (CVDs). In patients with CVDs and corresponding risk factors, the composition and ratio of gut microbiota have significant differences compared with their healthy counterparts. Therefore, gut microbiota dysbiosis, gut microbiota-generated metabolites, and the related signaling pathway may serve as explanations for some of the mechanisms about the occurrence and development of CVDs. Several studies have also demonstrated that many traditional and latest therapeutic treatments of CVDs are associated with the gut microbiota and its generated metabolites and related signaling pathways. Given that information, we summarized the latest advances in the current research regarding the effect of gut microbiota on health, the main cardiovascular risk factors, and CVDs, highlighted the roles and mechanisms of several metabolites, and introduced corresponding promising treatments for CVDs regarding the gut microbiota. Therefore, this review mainly focuses on exploring the role of gut microbiota related metabolites and their therapeutic potential in CVDs, which may eventually provide better solutions in the development of therapeutic treatment as well as the prevention of CVDs.

show abstract

Overview of bile acid signaling in the cardiovascular system

Cited by 21 publications

References 107 publications

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms

The role of the gut microbiota in health and cardiovascular diseases

Contact Info

Product

Resources

About